This cohort study examines changes in Medicare Advantage plan disenrollment following the development of new complex medical conditions and assesses heterogeneity by number of conditions, state Medigap policy, and plan characteristics.

This cross-sectional study assesses the association between the 2016 UK European Union membership referendum (Brexit) and changes in immigration of internationally trained physicians and nurses to the UK to fill vacancies in the National Health Service.

This Viewpoint advocates for multiyear enrollment for Medicare Advantage beneficiaries as a path toward greater investment in preventive and long-term care, reduced administrative costs, and more stable clinician relationships.

Policy expert says new California law highlights need for national standards on safety labels to cut high levels of U.S. food waste

2,500-year-old marble sculpture of young man hid face-down for centuries, broken and recycled as paving stones

Med School lecturer nods to wider implications in blueprint for Hungary

Research details answer to a question that’s more complex than it seems

Martha Ackmann tells Radcliffe audience the origin story of a songwriting legend

The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more. The post Editors’ Picks, August 2026: Weight Loss and Breast Cancer Biomarkers,...

Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are creating new possibilities...

This JAMA Forum discusses excess general fund revenue financing and the reasons why new reform priorities are needed for Medicare.

This cross-sectional study reports on changes in outpatient and telehealth visits among patients likely to be undocumented after the implementation of anti-immigration policies.

Health Policy

This post hoc analysis of a cluster randomized clinical trial aims to determine whether availability of a real-time prescription benefit tool increases prescription fill rates.

Chan School expert links soaring costs to broader policy shifts in ‘America’s Wrong Turn’

How former Harvard classmates binge-watched and buzzed their way to victory

Jon Star, professor of teaching and learning, finds flexibility is key to helping students master math

Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches. The post Smart Chemotherapy Gets...

A variety of national and local news outlets have highlighted AACR initiatives and experts in recent weeks. Learn about the news stories covering the findings from the AACR Cancer Disparities Progress Report 2026 and AACR's statement about the White House...

Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved by the FDA, and more. The post What...

This cohort study examines changes in Medicare Advantage plan disenrollment following the development of new complex medical conditions and assesses heterogeneity by number of conditions, state Medigap policy, and plan characteristics.

Health Policy

This cohort study assesses whether state eviction moratoria are associated with foster care entries across 60 US jurisdictions.

Research details answer to a question that’s more complex than it seems

Blood samples routinely collected at birth could be used for genetic testing, potentially helping 1,000 children a year, study suggests

We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for drug discovery. The post AACR D3...

Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches. The post Smart Chemotherapy Gets...

Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved by the FDA, and more. The post What...

With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the treatment of blood cancers in recent years. Here, we provide an overview of how this therapy works and which cancers it’s...

During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO, PhD (hc), FAACR; Keith T. Flaherty MD, FAACR; Lillian L. Siu, MD, FAACR; and Timothy A. Yap, MBBS, PhD—led a panel...